Company
Investment-firm
Financing round
General
About Company
Industry
Sector :
Subsector :
Keywords :
Contacts
location
Contact Email
Phone number
Website URL
Similar Companies1000
OrbiMed
OrbiMed is a healthcare-focused investment firm managing approximately $5 billion in assets.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Galen Partners
Galen Partners is a leading healthcare venture capital firm based in Stamford, Connecticut.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
YuanMing Capital
YuanMing Capital is a healthcare specialty fund that focuses on China-US cross-border investments.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Ivy Capital Partners
Ivy Capital Partners invests in musculoskeletal healthcare companies for long-term value creation.
Sector
Subsector
Location
count Of Investments
count Of Exists
Financials
Investments186
Celcuity
Celcuity is a biotech company that expands cancer treatment options through new cancer sub-type discoveries.
Sector
Subsector
Keywords
Location
total rounds
total raised
Ajax Therapeutics
Ajax Therapeutics develops therapies to target cytokine signaling pathways that drive hematologic malignancies.
Sector
Subsector
Location
total rounds
total raised
Zenas BioPharma
Zenas BioPharma develops immune-based therapies to transform patients' lives.
Sector
Subsector
Location
total rounds
total raised
Co-Investors
Acquisitions2
Serán Bioscience acquired by Vivo Capital
acquirer
date
type
Serán Bioscience
Serán is a contract development and manufacturing organization that provides services to pharmaceutical and biotechnology companies.
Sector
Subsector
Location
total rounds
Angiotech Pharmaceuticals acquired by Vivo Capital
acquirer
date
type
Angiotech Pharmaceuticals
Angiotech is a global pharmaceutical company that enhances the performance of medical devices and biomaterials using pharmacotherapeutics.
Sector
Subsector
Keywords
Location
total rounds
Exits30
Sagent Pharmaceuticals
Sagent Pharmaceuticals is a specialty pharmaceutical company.
Sector
Subsector
Keywords
Location
total rounds
total raised
Sierra Oncology
Sierra Oncology is a late-stage biopharmaceutical company focused on developing targeted therapies for rare forms of cancer.
Sector
Subsector
Keywords
Location
total rounds
total raised
Semnur Pharmaceuticals
Semnur Pharmaceuticals develops non-opioid drugs for back pain treatment.
Sector
Subsector
Location
total rounds
total raised
People
Founders2
Edgar G. Engleman
Dr. Edgar G. Engleman is the Member Of The Board Of Directors at Capia since 2001.He is a Founding Member of Vivo Ventures, LLC (formerly BioAsia Investments).Dr. Engleman is Professor of Pathology and Medicine at Stanford University School of Medicine, where he oversees the Stanford Blood Center and his own immunology research group. An editor of numerous scientific journals and the inventor of multiple patented technologies, Dr. Engleman has authored more than 250 publications in medical and scientific journals and has trained more than 200 graduate students and postdoctoral fellows. He has co-founded a number of biopharmaceutical companies including Cetus Immune, Genelabs, National Medical Audit and Dendreon. He is the lead inventor of the technology underlying Provenge, Dendreon's cancer vaccine, which was shown to extend life for patients with metastatic prostate cancer with remarkably few side effects. Provenge is the first active immunotherapeutic agent to be approved by the FDA (in 2010).Dr. Engleman currently serves on the boards of several private biotechnology companies. He received his BA from Harvard University and his MD from Columbia University School of Medicine.
current job
Edgar G. Engleman
Frank Kung
Dr. Kung is a founding member of Vivo Ventures, LLC (formerly BioAsia Investments), a healthcare/biotechnology venture capital management firm in Palo Alto, California. Dr. Kung started his career in the biotechnology industry in 1979 when he joined Cetus Corporation. He later co-founded Cetus Immune Corporation in 1981, which was acquired by its parent company in 1983. In 1984 he co-founded Genelabs Technologies, Inc. (NADSAQ: GNLB) where he served as Chairman and CEO until 1995. During his tenure in Genelabs, he brought the company public in 1991, and built it to a 175 employee international biotech company with operations in the United States, Belgium, Singapore, Switzerland and Taiwan. Dr. Kung received his B.S. in chemistry from the National Tsing Hua University in Taiwan, his Ph.D. in molecular biology and M.B.A. from the University of California, Berkeley. He received the Best Use of Technology Award from the Governor of California, the Entrepreneur of the Year Awards from Ernst and Young, and the Asian Business League. He also served on the board of directors of the Emerging Company Governing Body of the Biotechnology Industry Organization (BIO); Mt. Jade Science and Technology Association, West Coast; and the Asian American Manufacturing Association. He was appointed by the U.S. Secretary of Health and Human Services as a voting member of the National Biotechnology Policy Board. Dr. Kung currently serves on the board of directors of a number of emerging healthcare and biotechnology companies. Dr. Kung is a founding member of Vivo Ventures, LLC. Dr. Kung started his career in the biotechnology industry in 1979 when he joined Cetus Corporation. He later co-founded Cetus Immune Corporation which was acquired by its parent company in 1983. In 1984 he co-founded Genelabs Technologies, Inc. (NADSAQ:GNLB) where he served as Chairman and CEO until 1995. During his tenure in Genelabs, he brought the company public and built it to an international biotech company with operations in the United States, Belgium, Singapore, Switzerland and Taiwan. Dr. Kung received the Best Use of Technology Award from the Governor of California, the Entrepreneur of the Year Awards from Ernst and Young, and the Asian Business League. He was also appointed by the U.S. Secretary of Health and Human Services as a voting member of the National Biotechnology Policy Board.
current job
Frank Kung
Employee Profiles46
Activity
Recent News12
The graph reveals the ratio (%) of positive news articles in a chosen time range